Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;2000(2):CD001419.
doi: 10.1002/14651858.CD001419.

Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC)

Sarcoma Meta‐analysis Collaboration (SMAC) ‐ see acknowledgement section for list of authors  1
Affiliations

Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC)

Sarcoma Meta‐analysis Collaboration (SMAC) ‐ see acknowledgement section for list of authors. Cochrane Database Syst Rev. 2000.

Update in

Abstract

Background: Individually, randomised trilas have not shown conclusively whether adjuvant chemotherapy benefits adult patients with localised resectable soft-tissue sarcoma.

Objectives: Adjuvant chemotherapy aims to lessen the recurrence of cancer after surgery with or without radiotherapy. The objective of this review was to assess the effects of adjuvant chemotherapy in adults with resectable soft tissue sarcoma after such local treatment.

Search strategy: We searched the Cochrane Controlled Trials Register, UKCCCR Register of Cancer Trials, Physicians Data Query, EMBASE, MEDLINE and CancerLit.

Selection criteria: Randomised trials of adjuvant chemotherapy after local treatment in adults with localised resectable soft tissue sarcoma were included. Only trials in which accrual was completed by December 1992 were included.

Data collection and analysis: Individual patient data were obtained. Accuracy of data and quality of randomisation and follow-up of trials was assessed.

Main results: Fourteen trials of doxorubicin-based adjuvant chemotherapy involving 1568 patients were included. Median follow-up was 9.4 years. For local recurrence-free interval the hazard ratio with chemotherapy was 0.73 (95% Confidence Interval 0.56-0.94). For distant recurrence-free interval it was 0. 70 (95% CI 0.57-0.85). For overall recurrence-free survival it was 0. 75 (95% CI 0.64-0.87). These correspond to significant absolute benefits of 6-10% at 10 years. For overall survival the hazard ratio of 0.89 (95% CI 0.76-1.03) was not significant but potentially represents an absolute benefit of 4% (95% CI -1 to 9) at 10 years. There was no consistent evidence of a difference in effect according to age, sex, stage, site, grade, histology, extent of resection, tumour size or exposure to radiotherapy. However, the strongest evidence of a beneficial effect on survival was shown in patients with sarcoma of the extremities.

Reviewer's conclusions: Doxorubicin-based adjuvant chemotherapy appears to significantly improve time to local and distant recurrence and overall recurrence-free survival in adults with localised resectable soft tissue sarcoma. There is some evidence of a trend towards improved overall survival.

PubMed Disclaimer

Conflict of interest statement

There is no known conflict of interest.

Figures

1.1
1.1. Analysis
Comparison 1 Effects of adjuvant chemotherapy, Outcome 1 Local Recurrence‐free Interval.
1.2
1.2. Analysis
Comparison 1 Effects of adjuvant chemotherapy, Outcome 2 Distant Recurrence‐free Interval.
1.3
1.3. Analysis
Comparison 1 Effects of adjuvant chemotherapy, Outcome 3 Overall Recurrence‐free Survival.
1.4
1.4. Analysis
Comparison 1 Effects of adjuvant chemotherapy, Outcome 4 Overall Survival.
2.1
2.1. Analysis
Comparison 2 Subgroup analysis, Outcome 1 Overall Survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Bergonie 1981 {published and unpublished data}
    1. Ravaud A, Bui BB, Coindre J‐M, Kantor G, Stöckle E, Lagarde P, et al. Adjuvant chemotherapy with cyvadic in high risk soft tissue sarcoma: a randomised prospective trial. In: Salmon SE editor(s). Adjuvant therapy of cancer VI. Philadelphia: Saunders, W.B., 1990:556‐66.
DFCI/MGH 1978 {published and unpublished data}
    1. Antman K, Suit H, Amato D, Corson J, Wood W, Proppe K, et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. Journal of Clinical Oncology 1984;2(6):601‐8. - PubMed
ECOG 1978 {published and unpublished data}
    1. Lerner HJ, Amato DA, Savlov ED, DeWys WD, Mittelman A, Urtasun RC, et al. Eastern Cooperative Oncology Group: A comparison of adjuvant doxorubicin and observation for patients with localized soft tissue sarcoma. Journal of Clinical Oncology 1987;5(4):613‐7. - PubMed
EORTC 1977 {published and unpublished data}
    1. Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt‐Koops H, Buesa J, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma ‐ reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology 1994;12(6):1137‐49. - PubMed
GOG 1973 {published and unpublished data}
    1. Omura GA, Blessing JA, Major F, Liftshitz S, Ehrlich CE, Mangan C, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 1985;3(9):1240‐5. - PubMed
IGSC 1983 {published and unpublished data}
    1. Antman K, Ryan L, Borden E, Wood WC, Lerner HJ, Corson JM, et al. Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year results and review of the literature. In: Salmon SE editor(s). Adjuvant therapy of cancer VII. Philadelphia: W.B. Saunders, 1990:529‐43.
    1. Baker LH. Adjuvant therapy for soft tissue sarcomas. In: Ryan JR, Baker LH editor(s). Recent Concepts in Sarcoma Treatment. Dordecht: Kluwer Academic Publishers, 1988:130‐5.
Mayo 1975 {published and unpublished data}
    1. Edmonson JH. Systemic chemotherapy following complete excision of nonosseous sarcomas: Mayo Clinic Experience. Cancer Treatment Symposia 1985;3:89‐97.
    1. Edmonson JH, Fleming TR, Ivins JC, Burgert EO, Jr, Soule EH, O'Connell MJ, et al. Randomized study of systemic chemotherapy following complere excision of nonosseous sarcomas. Journal of Clinical Oncology 1984;2(12):1390‐6. - PubMed
MDA 1973 {published and unpublished data}
    1. Benjamin RS, Terjanian TO, Fenoglio CJ, Barkley HT, Evans HL, Murphy WK, et al. The importance of combination chemotherapy for adjuvant treatment of high‐risk patients with soft‐tissue sarcomas of the extremities. In: Salmon SE editor(s). Adjuvant therapy of cancer V. Orlando: Grune & Stratton, 1987:735‐44.
NCI4 1977 {published and unpublished data}
    1. Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, et al. Adjuvant chemotherapy for patients with high‐grade soft‐tissue sarcomas of the extremity. Journal of Clinical Oncology 1988;6(9):1491‐500. - PubMed
    1. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 1983;52:424‐34. - PubMed
NCI5 1977 {published and unpublished data}
    1. Glenn J, Kinsella T, Glatstein E, Tepper J, Baker A, Sugarbaker P, et al. A randomized prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. Cancer 1985;55:1206‐14. - PubMed
    1. Glenn J, Sindelar WF, Kinsella T, Glatstein E, Tepper J, Gosta J, et al. Results of multimodality therapy of resectable soft‐tissue sarcomas of the retroperitoneum. Surgery 1985;97(3):316‐25. - PubMed
NCI6 1977 {published and unpublished data}
    1. Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, et al. Adjuvant chemotherapy for patients with high‐grade soft‐tissue sarcomas of the extremity. Journal of Clinical Oncology 1988;6(9):1491‐500. - PubMed
    1. Rosenberg SA, Tepper J, Glatstein E, et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 1983;52:424‐34. - PubMed
Rizzoli 1981 {published and unpublished data}
    1. Gherlinzoni F, Bacci G, Picci P, Capanna R, Calderoni P, Lorenzi EG, et al. A randomized trial for the treatment of high‐grade soft‐tissue sarcomas of the extremities: preliminary observations. Journal of Clinical Oncology 1986;4(4):552‐8. - PubMed
    1. Picci P, Bacci G, Gherlinzoni F, Capanna R, Mercuri M, Ruggieri P, et al. Results of a randomised trial for the treatment of localized soft tissue tumors (STS) of the extremities in adult patients. In: Ryan JR, Baker LH editor(s). Recent Concepts in Sarcoma Treatment. Dordecht: Kluwer Academic Publishers, 1988:144‐8.
SAKK 57/87 {unpublished data only}
    1. SAKK. Randomized study of adjuvant chemotherapy with adriamycin and ifosfamide versus observation in patients with soft‐tissue sarcomas of extremity and trunk. Data on file Unpublished.
SSG 1981 {published and unpublished data}
    1. Alvegård TA, Sigurdsson H, Mouridsen H, Solheim Ø, Unsgaard B, Ringborg U, et al. Adjuvant chemotherapy with doxorubicin in high‐grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. Journal of Clinical Oncology 1989;7(10):1504‐13. - PubMed

References to studies excluded from this review

Baker 1987 {published data only}
    1. Baker LH, Franks J, Fine G, Balcerzak SP, Stephens RL, Stuckey WJ, et al. Combination chemotherapy using Adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomised comparative trial, A phase III, Southwest Oncology Group Study. Journal of Clinical Oncology 1987;5(6):851‐61. - PubMed
Borden 1990 {published data only}
    1. Borden EC, Amato DA, Edmonson JH, Ritch PS, Shiraki M. Randomized comparison of doxorubicin and vindesinme to doxorubicin for patients with metastatic soft‐tissue sarcomas. Cancer 1990;66:862‐7. - PubMed
Eilber 1988 {published data only}
    1. Eilber FR, Giuliano AE, Huth JF, Morton DL. A randomised prospective trial using postoperative adjuvant chemotherapy (Adriamycin) in high‐grade extremity soft‐tissue sarcoma. American Journal of Clinical Oncology 1988;11(1):39‐45. - PubMed
EST‐3782 {unpublished data only}
    1. IGSC. A randomized trial of adjuvant doxorubicin (Adriamycin) versus standard therapy (a delay of chemotherapy until the time of possible relapse. Data on file Unpublished.
Frustaci 1987 {published data only}
    1. Frustaci S, Gherlinzoni F, Paoli A, Pignatti G, Zmerly H, Azzarelli A, Comandone A, Buonadonna A, Olmi P, Ippolito V, Barbieri E, Apice G, Zakotnic B, Bacci G, Picci P, on behalf of the National Research Council (Italy). Preliminary results of an adjuvant randomized trial on high risk extremity soft tissue sarcomas (STS). The interim analysis. Proceedings of the American Society of Clinical Oncology. 1997; Vol. 16:696a, A1785.
Kinsella 1988 {published data only}
    1. Kinsella T, Sindelar W, Lack E, Glatstein E, Rosenberg SA. Kinsella T, Sindelar W, Lack E, Glatstein E, Rosenberg SA. Journal of Clinical Oncology 1988;6:18‐25. - PubMed
NCI‐92‐C‐0210 {unpublished data only}
    1. NCI. Phase III randomized trial of adjuvant DOX/IFF vs no adjuvant chemotherapy following complete resection of adult high‐grade soft tissue sarcoma confined to an extremity. Data on file Unpublished.
Pinedo 1988 {published data only}
    1. Pinedo HM, Verweij J. The treatment of soft tissue sarcomas with focus on chemotherapy: a review. Radiotherapeutic Oncology 1986;5:193‐205. - PubMed
Piver 1988 {published data only}
    1. Piver MS, Lele SB, Marchetti DL, Emrich LJ. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. Journal of Surgical Oncology 1988;38:233‐9. - PubMed
Schoenfeld 1982 {published data only}
    1. Schoenfeld DA, Roesenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC. A comparison of Adriamycin versus Vincristine and Adraimycin, and Cyclosphosphamide versus Vincristine, Actinomycin‐D, and Cyclophosphamide for advanced sarcoma. Cancer 1982;50:2757‐62. - PubMed
SWOG‐8791 {unpublished data only}
    1. SWOG. Phase III randomized study of adjuvant chemotherapy with ADR/DTIC/IPP vs no adjuvant therapy following resection with or without irradiation of adult grage III soft tissue sarcomas. Data on file Unpublished.

References to ongoing studies

EORTC 62931 {published data only}
    1. Phase II randomized study of adjuvant high‐dose DOX/IFF with G‐CSFvs no adjuvant chemotherapy for high‐grade soft tissue sarcoma. Ongoing study Starting date of trial not provided. Contact author for more information.

Additional references

Benjamin 1975
    1. Benjamin R, Weirnick P, Bachur N. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Medical and Pediatric Oncology 1975;1:63‐76. - PubMed
Blum 1974
    1. Blum RH, Carter SK. A new anticancer drug with significant clinical activity. Annals of Internal Medicine 1974;80(2):249‐59. - PubMed
Collins 1987
    1. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate effects of treatment effects: the need for systematic overviews. Statistics in Medicine 1987;6:245‐50. - PubMed
Delaney 1991
    1. Delaney TF, Yang JC, Glatstein E. Adjuvant therapy for adult patients with soft tissue sarcomas. Oncology 1991;5(6):105‐18. - PubMed
Dickersin 1995
    1. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. In: Chalmers I, Altman DG editor(s). Systematic Reviews. London: BMJ Publishing Group, 1995:17‐36. - PMC - PubMed
Freedman 1982
    1. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine 1982;1:121‐9. - PubMed
Gottlieb 1975
    1. Gottlieb JA, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, et al. Adriamycin (NSC‐123127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemotherapy Reports Part 3 1975;6(2):271‐82.
Jones 1994
    1. Jones GW, Chouinard M, Patel M. Adjuvant adriamycin (doxorubicin) in adult patients with soft‐tissue sarcomas: A systematic overview and quantitative meta‐analysis. Clinical Investigations in Medicine 1994;14 Suppl 19:A772.
Kaplan 1958
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. Journal of the American Statistical Association 1958;53:457‐81.
McGrath 1995
    1. McGrath PC, Sloan DA, Kenady DE. Adjuvant therapy of soft‐tissue sarcomas. Clinics in Plastic Surgery 1995;22(1):21‐9. - PubMed
Mertens 1995
    1. Mertens WC, Bramwell VHC. Adjuvant chemotherapy for soft tissue sarcomas. Hematology/Oncology Clinics of North America 1995;9(4):801‐15. - PubMed
Tierney 1995
    1. Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MKB. Adjuvant chemotherapy for soft‐tissue sarcoma: review and meta‐analysis of the published results of randomised clinical trials. British Journal of Cancer 1995;72:469‐75. - PMC - PubMed
Yusuf 1985
    1. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta‐blockade during and after myocardial infarction: An overview of the randomised trials. Progress in Cardiovascular Diseases 1985;27(5):335‐71. - PubMed
Zalupski 1993
    1. Zalupski MM, Ryan JR, Hussein ME, Baker LH. Defining the role of adjuvant chemotherapy for patients with soft tissue sarcoma of the extremities. In: Salmon SE editor(s). Adjuvant Therapy of Cancer VII. Philadelphia: JB Lippincott Company, 1993:385‐92.

References to other published versions of this review

SMAC 1997
    1. Sarcoma Meta‐analysis Collaboration. Adjuvant chemotherapy for localised resectable soft‐tissue sarcoma of adults: meta‐analysis of individual data. The Lancet 1997;350:1647‐54. - PubMed

Publication types

MeSH terms